SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical–protein interactome

Serious adverse drug reactions (SADRs) are caused by unexpected drug-human protein interactions, and some polymorphisms within binding pockets make the population carrying these polymorphisms susceptible to SADR. Predicting which populations are likely to be susceptible to SADR will not only strengthen drug safety, but will also assist enterprises to adjust R&D and marketing strategies. Making such predictions has recently been facilitated by the introduction of a web server named SePreSA. The server has a comprehensive collection of the structural models of nearly all the well known SADR targets. Once a drug molecule is submitted, the scale of its potential interaction with multi-SADR targets is calculated using the DOCK program. The server utilizes a 2-directional Z-transformation scoring algorithm, which computes the relative drug-protein interaction strength based on the docking-score matrix of a chemical-protein interactome, thus achieve greater accuracy in prioritizing SADR targets than simply using dock scoring functions. The server also suggests the binding pattern of the lowest docking score through 3D visualization, by highlighting and visualizing amino acid residues involved in the binding on the customer's browser. Polymorphism information for different populations for each of the interactive residues will be displayed, helping users to deduce the population-specific susceptibility of their drug molecule. The server is freely available at http://SePreSA.Bio-X.cn/.

[1]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[2]  Martine Bagot,et al.  Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. , 2002, The Journal of investigative dermatology.

[3]  C. Furberg,et al.  Adverse cardiovascular effects of rofecoxib. , 2006, The New England journal of medicine.

[4]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[5]  Yi Wang,et al.  DITOP: drug-induced toxicity related protein database , 2007, Bioinform..

[6]  W. Pichler,et al.  Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones. , 2001, International immunology.

[7]  The UniProt Consortium,et al.  The Universal Protein Resource (UniProt) 2009 , 2008, Nucleic Acids Res..

[8]  W. Pichler,et al.  Degeneracy and additional alloreactivity of drug-specific human αβ+ T cell clones , 2001 .

[9]  Yi Wang,et al.  In silico search of putative adverse drug reaction related proteins as a potential tool for facilitating drug adverse effect prediction. , 2006, Toxicology letters.

[10]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[11]  Robert A Hegele,et al.  Genetic determinants of statin intolerance , 2007, Lipids in Health and Disease.

[12]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Yu Zong Chen,et al.  Drug Adverse Reaction Target Database (DART) , 2003, Drug safety.

[14]  Todd J. A. Ewing,et al.  DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..

[15]  D G Myszka,et al.  High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE. , 2001, Analytical biochemistry.

[16]  Xiaomin Luo,et al.  TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..

[17]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[18]  C. L. Chepanoske,et al.  Ampicillin/penicillin‐binding protein interactions as a model drug‐target system to optimize affinity pull‐down and mass spectrometric strategies for target and pathway identification , 2005, Proteomics.

[19]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[20]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[21]  Russell A. Wilke,et al.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges , 2007, Nature Reviews Drug Discovery.

[22]  John A. Baron,et al.  Drs. Bresalier and Baron respond [3] , 2006 .

[23]  Ying Sun,et al.  A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir , 2007, Cell Research.

[24]  R. Rando,et al.  Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafness. , 1997, Biochemistry.

[25]  W. Pichler,et al.  Modes of presentation of chemical neoantigens to the immune system. , 2002, Toxicology.

[26]  Stephen A. Cammer SChiSM2: creating interactive web page annotations of molecular structure models using Jmol , 2007, Bioinform..

[27]  W. Pichler,et al.  Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. , 1997, The Journal of clinical investigation.

[28]  S. Green,et al.  A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. , 1993, The Journal of biological chemistry.

[29]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[30]  A. Need,et al.  Priorities and standards in pharmacogenetic research , 2005, Nature Genetics.